Brazil’s health regulator, Anvisa, cleared the first human trial of Vivaxin, a vaccine targeting malaria caused by the Plasmodium vivax parasite. The approval came through Resolution-RE No. 3,956 on October 6, 2026, and appeared in the federal official gazette Wednesday, October 7. For the 118,037 Brazilians who contracted malaria in 2025—more than 99% of them in the Amazon region—the decision offers a potential breakthrough against a disease that keeps workers from their jobs and drains communities of economic vitality.
The CTVacinas centre at the Federal University of Minas Gerais (UFMG), the University of São Paulo (USP), and laboratory Cristália developed the vaccine jointly. It’s a product of public research institutions and publicly funded science. Brazil’s science ministry, its national science fund, the Finep innovation agency, and the Ministry of Health backed the project. Their support shows why basic medical research often needs sustained public investment to tackle diseases that primarily affect lower-income populations who can’t generate profitable markets for pharmaceutical companies.
A Disease of the Vulnerable
Plasmodium vivax caused about 63% of estimated malaria cases across the Americas in 2024, according to the World Health Organization’s World Malaria Report. Yet no vaccine against vivax malaria is available to the public anywhere in the world. The gap doesn’t exist because the science is impossible, but because the disease mainly affects people in regions with limited purchasing power. The WHO-recommended vaccines RTS,S and R21/Matrix-M target Plasmodium falciparum, which dominates in sub-Saharan Africa, where global health initiatives have concentrated resources. Vivaxin addresses a neglected problem.
Ricardo Gazzinelli, who coordinates CTVacinas, stressed that malaria keeps people from working and carries substantial socioeconomic consequences. The disease doesn’t just sicken individuals; it weakens entire communities’ ability to earn and develop. Brazil’s Amazon region, where more than 99% of the nation’s cases occur, bears the heaviest burden. These often remote areas already have limited healthcare access, and economic opportunities depend on a healthy workforce.
How the Trial Works
The Phase 1 trial will enroll 48 healthy volunteers aged 18 to 59 who’ve never had malaria. Participants will receive three doses, spaced 28 days apart, and researchers will monitor them for 360 days. The double-blind, randomized, placebo-controlled trial meets rigorous scientific standards. It will take place at the clinical research centre of the Hospital das Clínicas of UFMG in Belo Horizonte, Minas Gerais state.
Phase 1 trials examine safety, injection reactions, and immune response—not whether the vaccine actually prevents infection. Later trial phases must establish that. Developers say mouse studies showed the formulation fully prevented infection in some animals, but caution that animal results don’t reliably predict human responses. Vaccines that work in laboratories can fail in people. Years of additional research lie ahead before any public approval becomes possible.
The Science Behind Vivaxin
Vivaxin combines three variants of a parasite surface protein called PvCSP in one molecule. The goal is to block the parasite before it reaches the liver, where it multiplies and causes disease. The approach draws on years of basic research into how the vivax parasite functions and where a vaccine might intervene most effectively. It’s the kind of foundational scientific work that requires sustained funding and brings no immediate commercial returns.
Brazilian public institutions developed this vaccine independently, and that matters. It shows that countries needn’t rely solely on multinational pharmaceutical corporations to tackle diseases affecting their populations. Public research centres, universities, and government funding produced a vaccine candidate that might eventually serve millions across the Americas. This model of public-sector drug development deserves expansion.
Anvisa’s approval to proceed with human trials marks a crucial step, but it’s only the beginning. Recruitment hasn’t started, and no timeline for results or advancement to protection trials has been announced. People heading to the Amazon should continue following medical prevention advice: malaria prevention remains the immediate responsibility, not a future vaccine.
Why This Matters:
Malaria disproportionately affects populations in lower-income regions with limited access to healthcare and economic opportunities. No vivax vaccine existed, even though the parasite caused 63% of malaria cases in the Americas. That gap reflects how market forces alone don’t address diseases affecting less affluent populations. Brazil’s public investment in Vivaxin through its science ministry, national research funds, and health ministry offers another model: governments and universities working together to develop treatments for neglected tropical diseases. If successful trials eventually lead to approval, this vaccine could restore economic productivity to entire communities while preventing suffering for hundreds of thousands. Years likely remain before public availability, underscoring why sustained, long-term public funding for basic medical research remains essential. Commercial incentives alone won’t close gaps in vaccine coverage.